A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Trial Details

NCT ID
NCT07005128
Phase
PHASE3
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tarlatamab
  • Durvalumab
  • Carboplatin
  • Etoposide
Locations (sample)
  • Casa Grande, Arizona, United States|32.8795,-111.75735
  • Hot Springs, Arkansas, United States|34.5037,-93.05518
  • Fullerton, California, United States|33.87029,-117.92534
  • Santa Monica, California, United States|34.01949,-118.49138
  • Grand Junction, Colorado, United States|39.06387,-108.55065

Key Eligibility Criteria

  • Participant has provided informed consent before initiation of any study-specific activities/procedures.
  • Age ≥ 18 years or ≥ legal age within the country if it is older than 18 years.
  • Histologically or cytologically documented ES-SCLC (American Joint Committee on Cancer, 2017, Stage IV SCLC \[T any, N any, M1 a/b/c\]), or T3 to T…
  • Measurable disease as defined per RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →